ArticleACS synthetic biology2025
minChemBio: Expanding Chemical Synthesis with Chemo-Enzymatic Pathways Using Minimal Transitions.
Article in ACS synthetic biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- AI-driven computational drug design: tools, workflow and challenges.RSC advances · 2026Review
- A Comprehensive Review of Recent Advances in Sustainable Synthesis of Bio-Based Furanic Compounds Via Chemical, Biological, Chemobiological and Other Combination Approach in Benign Systems.Applied biochemistry and biotechnology · 2026Review
- TridentSynth: a webtool for the retrosynthesis of molecules using chimeric type I polyketide synthases and chemoenzymatic pathways.Nucleic acids research · 2026Article
- A virtual platform for automated hybrid organic-enzymatic synthesis planning.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemo-enzymatic pathway design aims to combine the strengths of enzymatic with chemical synthesis to traverse biomolecular design space more efficiently. While chemical reactions often struggle with regioselectivity and stereoselectivity, enzymatic conversions often encounter limitations of low enzyme activity or availability. Optimally integrating both approaches provides an opportunity to identify efficient pathways beyond the capabilities of either modality. Recently, studies have shown the advantage of leveraging enzymatic steps into industrial-scale chemical processes, such as for the blood sugar regulator Sitagliptin (Merck) and the HIV protease inhibitor Darunavir (Prozomix). Designing optimal chemo-enzymatic pathways is a complex task. It requires navigating a high-dimensional search space of potential reactions that combine individual chemical and biochemical steps while at the same time minimizing transitions between chemical catalysis and bioreactions. Here, we introduce an algorithmic approach, minChemBio, that relies on solving a mixed-integer linear programming (MILP) problem by optimally searching through known chemical and enzymatic steps extracted from the United States Patent Office (USPTO) and MetaNetX databases, respectively. minChemBio allows for the minimization of transitions between chemical and biological reactions in the pathway, thus reducing the need for costly separation and purification steps required. minChemBio was benchmarked on three case studies involving the synthesis of 2-5-furandicarboxylic acid, terephthalate, and 3-hydroxybutyrate. Identified designs included both established literature pathways as well as unexplored ones which were compared against pathways identified by existing retrosynthetic tools. minChemBio fills a current gap in the space of pathway retrosynthesis tools by controlling and minimizing the transitions between chemical catalysis and biocatalytic steps. It is accessible to users through open-source code (https://github.com/maranasgroup/chemo-enz).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.